FilingReader Intelligence
Lukang subsidiary gets erectile dysfunction drug approval
August 1, 2025 at 05:01 AM UTC•By FilingReader AI
Shandong Lukang Pharmaceutical's subsidiary received a drug registration certificate for vardenafil hydrochloride tablets, a 20mg treatment for male erectile dysfunction.
The subsidiary invested approximately 6.8 million yuan in R&D for the drug, which has been classified as a Class 4 chemical drug and deemed bioequivalent.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Shandong Lukang Pharmaceutical publishes news
Free account required • Unsubscribe anytime